{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:03:53Z","timestamp":1784534633435,"version":"3.55.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review summarizes current evidence linking triglyceride-rich lipoproteins (TRLs) to atherosclerotic cardiovascular disease (ASCVD) with emphasis on challenges in translating the epidemiological- and genetic epidemiological findings into therapeutic risk reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Elevated triglycerides and TRL-cholesterol are consistently associated with ASCVD risk in both primary- and secondary-prevention populations. Human genetic studies of pathways involving LPL, APOC3, ANGPTL3, and ANGPTL4 strongly support a causal role for TRL metabolism in atherosclerosis. The pathogenic effects of TRLs may differ from those of low-density lipoproteins (LDLs), with TRLs potentially contributing through both cholesterol deposition and activation of inflammatory pathways. However, therapeutic translation has been less straightforward than for LDL. Fibrates have produced inconsistent cardiovascular outcome results, icosapent ethyl reduces cardiovascular events but probably through mechanisms beyond triglyceride lowering alone, and potent APOC3 inhibition has failed to show short-term coronary plaque regression. Together, these findings suggest that TRLs are causal contributors to ASCVD, but that their therapeutic relevance may depend on disease stage, background LDL-C\/apoB burden, and residual metabolic risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>TRLs are biologically and genetically linked to ASCVD, but whether lowering TRLs translates into cardiovascular risk reduction may depend on background therapy and cardiovascular risk context. Future trials must determine whether TRL-targeted therapies reduce ASCVD events beyond contemporary prevention, and in which patients this residual risk remains modifiable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11883-026-01442-y","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:22:03Z","timestamp":1784532123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triglyceride-Rich Lipoproteins and ASCVD: Evidence for Causality and Challenges in Therapeutic Translation"],"prefix":"10.1007","volume":"28","author":[{"given":"Elias","family":"Bj\u00f6rnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Adiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"1442_CR1","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"PS Collaboration","year":"2007","unstructured":"Collaboration PS, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(07)61778-4.","journal-title":"Lancet"},{"key":"1442_CR2","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"ERF Collaboration","year":"2009","unstructured":"Collaboration ERF, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993\u20132000. https:\/\/doi.org\/10.1001\/jama.2009.1619.","journal-title":"JAMA"},{"key":"1442_CR3","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264\u201372. https:\/\/doi.org\/10.1056\/NEJMoa054013.","journal-title":"N Engl J Med"},{"key":"1442_CR4","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.09.017.","journal-title":"J Am Coll Cardiol"},{"key":"1442_CR5","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","volume":"65","author":"BA Ference","year":"2015","unstructured":"Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015;65:1552\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2015.02.020.","journal-title":"J Am Coll Cardiol"},{"key":"1442_CR6","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"key":"1442_CR7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","journal-title":"Lancet"},{"key":"1442_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(12)60367-5.","journal-title":"Lancet"},{"key":"1442_CR9","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"key":"1442_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"1442_CR11","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"1442_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289\u201397. https:\/\/doi.org\/10.1001\/jama.2016.13985.","journal-title":"JAMA"},{"key":"1442_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jama.2017.0972","volume":"317","author":"AV Khera","year":"2017","unstructured":"Khera AV, Won HH, Peloso GM, O\u2019Dushlaine C, Liu D, Stitziel NO, et al. Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease. JAMA. 2017;317:937\u201346. https:\/\/doi.org\/10.1001\/jama.2017.0972.","journal-title":"JAMA"},{"key":"1442_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1307095.","journal-title":"N Engl J Med"},{"key":"1442_CR15","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69:2054\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2017.02.030.","journal-title":"J Am Coll Cardiol"},{"key":"1442_CR16","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","volume":"374","author":"FE Dewey","year":"2016","unstructured":"Dewey FE, Gusarova V, O\u2019Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374:1123\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1510926.","journal-title":"N Engl J Med"},{"key":"1442_CR17","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"AD Pradhan","year":"2022","unstructured":"Pradhan AD, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387:1923\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2210645.","journal-title":"N Engl J Med"},{"key":"1442_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"key":"1442_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.126.080012","author":"NA Marston","year":"2026","unstructured":"Marston NA, Bergmark BA, Prohaska TA, Moura FA, Zimerman A, Alexander VJ, et al. Effect of APOC3 inhibition with olezarsen on coronary atherosclerosis: essence-TIMI 73b imaging study. Circulation. 2026. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.126.080012.","journal-title":"Circulation"},{"key":"1442_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/0002-8703(86)90296-6","volume":"112","author":"WP Castelli","year":"1986","unstructured":"Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J. 1986;112:432\u20137.","journal-title":"Am Heart J"},{"key":"1442_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/01.ATV.11.1.2","volume":"11","author":"MA Austin","year":"1991","unstructured":"Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2\u201314.","journal-title":"Arterioscler Thromb"},{"key":"1442_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0002-9343(86)90157-9","volume":"80","author":"WP Castelli","year":"1986","unstructured":"Castelli WP, Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986;80:23\u201332.","journal-title":"Am J Med"},{"key":"1442_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","volume":"3","author":"JE Hokanson","year":"1996","unstructured":"Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213\u20139.","journal-title":"J Cardiovasc Risk"},{"key":"1442_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","volume":"115","author":"N Sarwar","year":"2007","unstructured":"Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circ. 2007;115:450\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.637793.","journal-title":"Circ"},{"key":"1442_CR25","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1161\/01.CIR.0000145615.33955.83","volume":"110","author":"A Patel","year":"2004","unstructured":"Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2678\u201386. https:\/\/doi.org\/10.1161\/01.CIR.0000145615.33955.83.","journal-title":"Circulation"},{"key":"1442_CR26","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1161\/hc3501.095214","volume":"104","author":"AR Sharrett","year":"2001","unstructured":"Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities Study. Circulation. 2001;104:1108\u201313. https:\/\/doi.org\/10.1161\/hc3501.095214.","journal-title":"Circulation"},{"key":"1442_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.298.3.299","volume":"298","author":"BG Nordestgaard","year":"2007","unstructured":"Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299\u2013308. https:\/\/doi.org\/10.1001\/jama.298.3.299.","journal-title":"JAMA"},{"key":"1442_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.298.3.309","volume":"298","author":"S Bansal","year":"2007","unstructured":"Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309\u201316. https:\/\/doi.org\/10.1001\/jama.298.3.309.","journal-title":"JAMA"},{"key":"1442_CR29","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1001\/jama.2008.621","volume":"300","author":"JJ Freiberg","year":"2008","unstructured":"Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300:2142\u201352. https:\/\/doi.org\/10.1001\/jama.2008.621.","journal-title":"JAMA"},{"key":"1442_CR30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ana.22384","volume":"69","author":"A Varbo","year":"2011","unstructured":"Varbo A, Nordestgaard BG, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Benn M. Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Ann Neurol. 2011;69:628\u201334. https:\/\/doi.org\/10.1002\/ana.22384.","journal-title":"Ann Neurol"},{"key":"1442_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2012.08.1026.","journal-title":"J Am Coll Cardiol"},{"key":"1442_CR32","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","volume":"128","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128:1298\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.003008.","journal-title":"Circulation"},{"key":"1442_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1373\/clinchem.2017.279463","volume":"64","author":"A Varbo","year":"2018","unstructured":"Varbo A, Freiberg JJ, Nordestgaard BG. Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the Copenhagen General Population Study. Clin Chem. 2018;64:219\u201330. https:\/\/doi.org\/10.1373\/clinchem.2017.279463.","journal-title":"Clin Chem"},{"key":"1442_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","volume":"62","author":"AMK Jepsen","year":"2016","unstructured":"Jepsen AMK, Langsted A, Varbo A, Bang LE, Kamstrup PR, Nordestgaard BG. Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease. Clin Chem. 2016;62:593\u2013604. https:\/\/doi.org\/10.1373\/clinchem.2015.253757.","journal-title":"Clin Chem"},{"key":"1442_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1476-511X-12-159","volume":"12","author":"J Liu","year":"2013","unstructured":"Liu J, Zeng FF, Liu ZM, Zhang CX, Ling WH, Chen YM. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis. 2013;12:159. https:\/\/doi.org\/10.1186\/1476-511X-12-159.","journal-title":"Lipids Health Dis"},{"key":"1442_CR36","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345\u201352. https:\/\/doi.org\/10.1038\/ng.2795.","journal-title":"Nat Genet"},{"key":"1442_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB Jorgensen","year":"2014","unstructured":"Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1308027.","journal-title":"N Engl J Med"},{"key":"1442_CR38","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321:364\u201373. https:\/\/doi.org\/10.1001\/jama.2018.20045.","journal-title":"JAMA"},{"key":"1442_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003062","volume":"17","author":"TG Richardson","year":"2020","unstructured":"Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17:e1003062. https:\/\/doi.org\/10.1371\/journal.pmed.1003062.","journal-title":"PLoS Med"},{"key":"1442_CR40","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/ng.3561","volume":"48","author":"A Helgadottir","year":"2016","unstructured":"Helgadottir A, Gretarsdottir S, Thorleifsson G, Hjartarson E, Sigurdsson A, Magnusdottir A, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet. 2016;48:634\u20139. https:\/\/doi.org\/10.1038\/ng.3561.","journal-title":"Nat Genet"},{"key":"1442_CR41","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","volume":"44","author":"E Bj\u00f6rnson","year":"2023","unstructured":"Bj\u00f6rnson E, Adiels M, Taskinen MR, Burgess S, Rawshani A, Boren J, et al. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study. Eur Heart J. 2023;44:4186\u201395. https:\/\/doi.org\/10.1093\/eurheartj\/ehad337.","journal-title":"Eur Heart J"},{"key":"1442_CR42","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jacc.2024.07.034","volume":"84","author":"E Bj\u00f6rnson","year":"2024","unstructured":"Bj\u00f6rnson E, Adiels M, Gummesson A, Taskinen MR, Burgess S, Packard CJ, et al. Quantifying triglyceride-rich lipoprotein atherogenicity, associations with inflammation, and implications for risk assessment using non-HDL cholesterol. J Am Coll Cardiol. 2024;84:1328\u201338. https:\/\/doi.org\/10.1016\/j.jacc.2024.07.034.","journal-title":"J Am Coll Cardiol"},{"key":"1442_CR43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","volume":"27","author":"J Boren","year":"2016","unstructured":"Boren J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27:473\u201383. https:\/\/doi.org\/10.1097\/MOL.0000000000000330.","journal-title":"Curr Opin Lipidol"},{"key":"1442_CR44","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","volume":"72","author":"BA Ference","year":"2018","unstructured":"Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:1141\u201356. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.046.","journal-title":"J Am Coll Cardiol"},{"key":"1442_CR45","doi-asserted-by":"publisher","first-page":"120529","DOI":"10.1016\/j.atherosclerosis.2025.120529","volume":"410","author":"MJ Chapman","year":"2025","unstructured":"Chapman MJ, Packard CJ, Bj\u00f6rnson E, Ginsberg HN, Bor\u00e9n J. Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know. Atherosclerosis. 2025;410:120529. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120529.","journal-title":"Atherosclerosis"},{"key":"1442_CR46","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/MOL.0000000000000779","volume":"32","author":"JM Kraaijenhof","year":"2021","unstructured":"Kraaijenhof JM, Hovingh GK, Stroes ESG, Kroon J. The iterative lipid impact on inflammation in atherosclerosis. Curr Opin Lipidol. 2021;32:286\u201392. https:\/\/doi.org\/10.1097\/MOL.0000000000000779.","journal-title":"Curr Opin Lipidol"},{"key":"1442_CR47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MCO.0000000000000999","volume":"27","author":"D Elias-Lopez","year":"2024","unstructured":"Elias-Lopez D, Doi T, Nordestgaard BG, Kobylecki CJ. Remnant cholesterol and low-grade inflammation jointly in atherosclerotic cardiovascular disease: implications for clinical trials. Curr Opin Clin Nutr Metab Care. 2024;27:125\u201335. https:\/\/doi.org\/10.1097\/MCO.0000000000000999.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"1442_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119241","volume":"406","author":"D Elias-Lopez","year":"2025","unstructured":"Elias-Lopez D, Kobylecki CJ, Vedel-Krogh S, Doi T, Nordestgaard BG. Association of low-grade inflammation and elevated remnant cholesterol with risk of ASCVD and mortality in impaired renal function. Atherosclerosis. 2025;406:119241. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119241.","journal-title":"Atherosclerosis"},{"key":"1442_CR49","doi-asserted-by":"publisher","unstructured":"Morze J, Bj\u00f6rnson E, Mi MY, Adiels M, Melloni GE, Rosas da Silva G, et al. Plasma proteomic profiling reveals distinct roles of apolipoprotein B-containing lipoproteins in atherosclerosis. Res Square [Preprint]. 2025 Dec;19. https:\/\/doi.org\/10.21203\/rs.3.rs-8307321\/v1.","DOI":"10.21203\/rs.3.rs-8307321\/v1"},{"key":"1442_CR50","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"MH Frick","year":"1987","unstructured":"Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237\u201345. https:\/\/doi.org\/10.1056\/NEJM198711123172001.","journal-title":"N Engl J Med"},{"key":"1442_CR51","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410\u20138. https:\/\/doi.org\/10.1056\/NEJM199908053410604.","journal-title":"N Engl J Med"},{"key":"1442_CR52","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus: the FIELD study. Lancet. 2005;366:1849\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(05)67667-2.","journal-title":"Lancet"},{"key":"1442_CR53","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1001282.","journal-title":"N Engl J Med"},{"key":"1442_CR54","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"ORIGINT Investigators","year":"2012","unstructured":"Investigators ORIGINT, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1203859.","journal-title":"N Engl J Med"},{"key":"1442_CR55","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379:1540\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1804989.","journal-title":"N Engl J Med"},{"key":"1442_CR56","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids versus corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"key":"1442_CR57","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","volume":"41","author":"MJ Budoff","year":"2020","unstructured":"Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41:3925\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa652.","journal-title":"Eur Heart J"},{"key":"1442_CR58","doi-asserted-by":"publisher","first-page":"e013543","DOI":"10.1161\/JAHA.119.013543","volume":"8","author":"Y Hu","year":"2019","unstructured":"Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127,477 participants. J Am Heart Assoc. 2019;8:e013543. https:\/\/doi.org\/10.1161\/JAHA.119.013543.","journal-title":"J Am Heart Assoc"},{"key":"1442_CR59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med"},{"key":"1442_CR60","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","volume":"393","author":"BA Bergmark","year":"2025","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Targeting APOC3 with olezarsen in moderate hypertriglyceridemia. N Engl J Med. 2025;393:1279\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2507227.","journal-title":"N Engl J Med"},{"key":"1442_CR61","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024;391:899\u2013912. https:\/\/doi.org\/10.1056\/NEJMoa2404143.","journal-title":"N Engl J Med"},{"key":"1442_CR62","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9:620\u201330. https:\/\/doi.org\/10.1001\/jamacardio.2024.0959.","journal-title":"JAMA Cardiol"},{"key":"1442_CR63","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s11154-024-09893-x","volume":"25","author":"W Masson","year":"2024","unstructured":"Masson W, Lobo M, Nogueira JP, Corral P, Barbagelata L, Siniawski D. Inhibitors of apolipoprotein C3, triglyceride levels, and risk of pancreatitis: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2024;25:817\u201325. https:\/\/doi.org\/10.1007\/s11154-024-09893-x.","journal-title":"Rev Endocr Metab Disord"},{"key":"1442_CR64","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"N Engl J Med"},{"key":"1442_CR65","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","volume":"78","author":"Z Ahmad","year":"2021","unstructured":"Ahmad Z, Pordy R, Rader DJ, Rosenson RS, Genest J, Leiter LA, et al. Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia. J Am Coll Cardiol. 2021;78:193\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.091.","journal-title":"J Am Coll Cardiol"},{"key":"1442_CR66","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark BA, O\u2019Donoghue ML, Murphy SA, Kuder JF, Ezhov MV, Ceska R, et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145:1377\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059266.","journal-title":"Circulation"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01442-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01442-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01442-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:22:05Z","timestamp":1784532125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01442-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1442"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01442-y","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All studies with human or animal subjects are published and followed ethical standards.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.B. declares consultancy fees or honoraria from Arrowhead Pharmaceuticals, Amgen and Novartis and ongoing collaboration with Ribocure pharmaceuticals.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"74"}}